Clinical benefit has already been demonstrated with polymer–drug conjugates bearing classical chemotherapeutic agents. The future of cancer therapy will mainly rely on specific targets ...

Reactive end-groups on non-immunogenic biocompatible polymers, such as PEG ... while avoiding premature blood clearance and off-target toxicity. The installment of a biocompatible "stealth ...